{"entity":{"id":"yl202","kind":"drug","name":"YL202","aka":[],"tldr":"YL202 is an experimental antibody-drug conjugate (ADC) from MediLink Therapeutics (Suzhou) in phase 3 trials for non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and colorectal cancer, aimed at HER3.","summary":"YL202 is an antibody-drug conjugate (ADC) developed by MediLink Therapeutics (Suzhou). Its target is HER3 (the sponsor names HER3). ClinicalTrials.gov describes the intervention as: YL202 will be intravenously infused over 60±10 min. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07416994 (Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer) and NCT07461454 (YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer), in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, colorectal cancer and cervical cancer. The largest, NCT07416994, plans to enrol 440 participants with primary completion expected 2028-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of YL202","url":"https://clinicaltrials.gov/search?intr=YL202"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","breast-hr-positive","colorectal","cervical"],"sections":[],"technologies":[],"targets":["her3"],"drugs":[],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07416994","nct07461454","nct07169994","nct07202364","nct06107686","nct06439771"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"antibody-drug conjugate (ADC)","mechanism":"Antibody-drug conjugate (ADC) directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/yl202/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}],"trial":[{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","route":"/trials/nct06439771/"},{"id":"nct07169994","kind":"trial","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07169994/"},{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/"},{"id":"nct06107686","kind":"trial","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","route":"/trials/nct06107686/"},{"id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/"},{"id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/"}]}}